The findings hold particular promise for people who haven’t been helped by the targeted drug tagraxofusp.

Engineered T cells kept leukemia from returning in 12 high-risk patients.

The approvals amount to a “game-changer for how we think about treating different groups of patients with AML.”

Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.

Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”